Italy Builds Biotech Momentum As VC Base And Tech Transfer Improve, Despite Cultural Resistance

Italy’s biotech ecosystem is showing signs of becoming more investable in a durable way, according to investors interviewed by BioSpace, who pointed to improving tech transfer offices, a broader venture capital base and a talent pool helped by people returning from abroad.

The change matters because Italy has long had the scientific inputs for biotech company creation without reliably translating them into a consistent pipeline of startups. Investors now describe a setup that is still constrained by cultural resistance to commercialization, but better positioned to turn research output into companies that can attract capital and operate internationally.

The funding base is getting more consistent

According to the Nature Index, Italy ranks tenth globally and fourth in Europe for overall research output across 178 top journals. Fabrizio Calisti, medical director at Angelini Ventures, said the Lombardy region, with Milan as its capital, has historically driven innovation as the country’s financial center, while strong universities are distributed across Italy.

That research base feeds directly into startup creation because many Italian biotech companies emerge from university science, said Lorenzo Pradella, board director at Zcube. Calisti and Diana Saraceni, founder and managing partner at Panakès Partners, said tech transfer offices have become more efficient, which matters for turning academic work into companies and for attracting foreign capital.

Saraceni said the foundation for the current financing environment was laid about 10-15 years ago by Cassa Depositi e Prestiti, Italy’s national promotional institution and public development bank. She said CDP helped create incubators and backed several venture firms, helping build an ecosystem that now also attracts international capital. Even so, she added that capital today is overwhelmingly private.

Italy now has about a half-dozen local VCs active in biotech, according to Saraceni, and several have a corporate VC arm. Calisti said the VC network is also better connected with other European players. At the national level, he added, Italy’s multibillion National Recovery and Resilience Plan, funded through the E.U., has directed a fraction of funds toward biotech, medtech and tech transfer office investment.

The bottleneck is still cultural

The main limitation described by investors is not scientific quality but founder formation. Calisti and Saraceni said the idea of building startups from scientific research is still not widely embraced. Saraceni said researchers often prefer to continue academic work and may see making money from science as unethical.

That is a meaningful strategic constraint because better funding infrastructure alone does not ensure a stronger company pipeline. The more encouraging sign for investors is that the ecosystem appears to be improving on several fronts at once rather than depending on a single policy program or one funding source.

Calisti and Saraceni also pointed to “brain repatriation” as an advantage, with more Italians returning home with operating experience gained elsewhere. Saraceni said tax incentives have also attracted non-Italians in the sciences to move to the country.

What matters next

For investors, the next test is whether Italian biotech companies can scale without losing their Italian footprint. Calisti said relocation to larger hubs can be normal, but retaining value inside Italy is important if the country wants to build a self-reinforcing ecosystem rather than just produce early science for others to develop.

Manufacturing could help on that front. Calisti said Italy has a strong manufacturing base, which could provide one of the anchors that keeps more of the sector’s value in-country.

The signal from this market is not that Italy has solved its biotech commercialization gap. It is that the prerequisites for repeatable company creation appear stronger than they were before: more capital, more capable tech transfer, more returning talent and better European connectivity. If those pieces keep compounding, Italy’s scientific reputation may start to translate into a steadier class of globally competitive biotech companies.